enGene Confirms Corporate Name Change to enGene Therapeutics Inc enGene Therapeutics Inc., a clinical-stage biotechnology company focused on the development of non-viral genetic medicines, has announced that it will officially adopt its new corporate name, “enGene Therapeutics Inc.,” effective April…
Biocon Announces U.S. Commercial Debut of Bosaya™ and Aukelso™, Its Denosumab Biosimilars Biocon Limited, a global innovation-driven biopharmaceutical organization, has announced the commercial launch of two denosumab biosimilars—Bosaya™ and Aukelso™—in the United States, marking a significant expansion of its biosimilars…
Gilead to Acquire Tubulis to Enhance Oncology Portfolio with Potentially Best-in-Class ADC and Advanced Platform Gilead Sciences has announced that it has entered into a definitive agreement to acquire Tubulis GmbH, a Germany-based clinical-stage biotech specializing in next-generation antibody-drug conjugates…
Stoke Therapeutics Announces Appointment of Dr. Clare Kahn to Its Board of Directors Stoke Therapeutics, a clinical-stage biotechnology company focused on restoring protein expression through RNA-based medicines, has announced the appointment of Clare Kahn, Ph.D., to its Board of Directors.…
Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies for serious cardiovascular diseases, has announced a key regulatory milestone…
Armatus Reports Promising Breakthrough Data on TVR110, a Vectorized MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A Armatus Bio, a late-preclinical biotechnology company focused on developing next-generation vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of important…
PureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal PureTech Health plc, a clinical-stage biotherapeutics company focused on translating cutting-edge science into transformative therapies, has announced the publication of results from its Phase 2b…
PharmaEssentia Announces Investment Agreement to Build New Manufacturing Facility in Puerto Rico PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan, has taken a significant step in expanding its international manufacturing footprint with the signing of an investment agreement for…
Shape Memory Medical Initiates Patient Enrollment in FLAGSHIP Study of Novel False Lumen Embolization Technology Shape Memory Medical Inc. has announced a major clinical milestone with the enrollment of the first patients in its FLAGSHIP study, a first-in-human clinical trial…
Gilead Extends Tender Offer Timeline for Planned Acquisition of Arcellx Gilead Sciences, Inc. has announced an extension of its ongoing tender offer to acquire all outstanding shares of common stock of Arcellx, signaling continued progress in one of the more…
Shionogi Secures Complete Ownership of Global Rights to RADICAVA (edaravone) Shionogi & Co., Ltd. has announced the successful completion of a major strategic transaction involving the full transfer of rights to RADICAVA (edaravone), marking a significant milestone in the company’s…
Bristol Myers Squibb Strengthens and Expands Commitment to Advancing Equitable Care in Multiple Myeloma as GAAP Initiative Reaches Ten Years Bristol Myers Squibb (NYSE: BMY), a recognized leader in oncology, has announced a significant evolution of its long-standing “Standing in…